|
|
Zhang T, Hu S, Yang W, Zhang J, Wei W, Dai W, et al . Visual analysis of global research on neoadjuvant and adjuvant strategies in NSCLC from 2013 to 2023. Int J Radiat Res 2025; 23 (3) :527-533 URL: http://ijrr.com/article-1-6526-en.html
Department of Pulmonary and Critical Care Medicine, General Hospital of Western Theater Command, NO.270 Tianhui Road, Rongdu Avenue, Jinniu District, Chengdu, Sichuan Province 610083, China , Ma
Abstract: (549 Views)
Background: Although combination treatment strategies have significantly improved and achieved impressive results, the 5-year survival rate of non-small cell lung cancer (NSCLC) still remains undesirable. Given the rapidly burgeoning concept of neoadjuvant and adjuvant strategies in cancer for increasing the therapeutic benefit, we aimed to explore the importance and trends of adjuvant strategies in NSCLC. Materials and Methods: We performed a visual analysis to evaluate published literature (707 papers) in the field of neoadjuvant and adjuvant strategies in NSCLC from January 1, 2013 to July 6, 2023, and acquire a comprehensive understanding of the field. VOSviewer was used to construct bibliometric networks for 707 related literatures. Results: the counts of publications and the evolution of citations concerning neoadjuvant and adjuvant strategies in NSCLC from 2013 to 2023 indicated the increasing interest and investment in the field of NSCLC neoadjuvance and adjunctive strategies. We detected that the majority of academic papers on neoadjuvant and adjuvant strategies for NSCLC were published in high-quality journals. A keyword screening of the relevant literature showed that the research on neoadjuvant and adjuvant strategies for NSCLC was mainly related to chemotherapy. China and United States were particularly influential and highly prolific in this field. Conclusion: Given this rapidly expanding realm, the neoadjuvant and adjuvant strategies may further improve the prognosis of NSCLC. The visual analysis will promote the development of research on neoadjuvant and adjuvant strategies in NSCLC and provide a reference for further research in this field.
References
1. 1. Zeng H, Chen W, Zheng R, et al. (2018) Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 6(5): e555-e567. [ DOI:10.1016/S2214-109X(18)30127-X] 2. Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6): 394-424. [ DOI:10.3322/caac.21492] 3. Sung H, Ferlay J, Siegel RL, et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209-249. [ DOI:10.3322/caac.21660] 4. Kuroda H, Mochizuki S, Shimoda M, et al. (2010) ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int J Cancer, 127(8): 1844-56. [ DOI:10.1002/ijc.25212] 5. Wu H and Zhou C (2018) Long non-coding RNA UCA1 promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis. Biochem Biophys Res Commun, 496(2): 738-745. [ DOI:10.1016/j.bbrc.2018.01.097] 6. Zhang T, Ma L, Wu P, et al. (2019) Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non-small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway. Oncol Rep, 41(3): 1779-1788. [ DOI:10.3892/or.2019.6976] 7. Ghafouri-Fard S and Taheri M (2019) UCA1 long non-coding RNA: An update on its roles in malignant behavior of cancers. Biomed Pharmacother, 120: 109459. [ DOI:10.1016/j.biopha.2019.109459] 8. Chen P, Liu Y, Wen Y, et al. (2022) Non-small cell lung cancer in China. Cancer Commun (Lond), 42(10): 937-970. [ DOI:10.1002/cac2.12359] 9. Conroy MR, Dennehy C, Forde PM (2023) Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer. Lung Cancer, 183: 107314. [ DOI:10.1016/j.lungcan.2023.107314] 10. Fan Q, Hu X, Zhang H, et al. (2017) MiR-193a-3p is an important tumour suppressor in lung cancer and directly targets KRAS. Cell Physiol Biochem, 44(4): 1311-1324. [ DOI:10.1159/000485491] 11. Monastirioti A, Papadaki C, Rounis K, et al. (2021) A prognostic role for circulating micrornas involved in macrophage polarization in advanced non-small cell lung cancer. Cells, 10(8): 1988. [ DOI:10.3390/cells10081988] 12. Zeng Y, Wang G, Zheng H, et al. (2023) The effect of radiotherapy and surgery on stage IIIA/B NSCLC patients treated with chemotherapy. International Journal of Radiation Research. 21(3): 475-483. [ DOI:10.61186/ijrr.21.3.475] 13. Chaft JE, Shyr Y, Sepesi B, et al. (2022) preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol, 40(6): 546-555. [ DOI:10.1200/JCO.21.01589] 14. Broderick SR (2020) adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin, 30(2): 215-220. [ DOI:10.1016/j.thorsurg.2020.01.001] 15. Chmielewska I, Stencel K, Kalinka E, et al. (2021) neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer-clinical trials experience. Cancers (Basel), 13(20): 5048. [ DOI:10.3390/cancers13205048] 16. Yen PC, Chou W, Chien TW, et al. (2023) Analyzing fulminant myocarditis research trends and characteristics using the follower-leading clustering algorithm (FLCA): A bibliometric study. Medicine (Baltimore), 102(26): e34169. [ DOI:10.1097/MD.0000000000034169] 17. Chen X, Yu Y, Nie H, et al. (2023) Insights into adeno-associated virus-based ocular gene therapy: a bibliometric and visual analysis. Medicine (Baltimore), 102(24): e34043. [ DOI:10.1097/MD.0000000000034043] 18. Lin F, Xie M, Sheng X, et al. (2023) Research trends in the field of retinitis pigmentosa from 2002 to 2021: a 20 years bibliometric analysis. Int Ophthalmol, 43(6): 1825-1833. [ DOI:10.1007/s10792-022-02581-2] 19. Srivastava K and Saxena A (2023) Research landscape on student suicide: a bibliometric and visual analysis of 62 years (1959-2021). Indian J Psychol Med, 45(3): 237-242. [ DOI:10.1177/02537176231160658] 20. Wang, W., W. Sun, H. Xu, et al. (2023) Bibliometric analysis and mini-review of global research on pyroptosis in the field of cancer. Apoptosis, 28(7-8): 1076-1089. [ DOI:10.1007/s10495-023-01821-9] 21. Lini L, Rong X, Wei H, et al. (2023) Characteristics and research status among clinical trials in cardio-oncology by bibliometric and visualized analysis. Cancer Med, 12(11): 12535-12547. [ DOI:10.1002/cam4.6045] 22. Zhou X, Luo F, Shi G, et al. (2023) Depression and macrophages: A bibliometric and visual analysis from 2000 to 2022. Medicine (Baltimore), 102(26): e34174. [ DOI:10.1097/MD.0000000000034174] 23. Yang J, Wu J, Han T, et al. (2023) Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study. Medicine (Baltimore), 102(24): e34002. [ DOI:10.1097/MD.0000000000034002] 24. Li H, Liu T, Yang L, et al. (2024) Knowledge landscapes and emerging trends of cardiorenal syndrome type 4: a bibliometrics and visual analysis from 2004 to 2022. Int Urol Nephrol, 56(1): 155-166. [ DOI:10.1007/s11255-023-03680-4] 25. Li X, Lian Y, Pan F, et al. (2023) Global research trends in prediction of difficult airways: A bibliometric and visualization study. Medicine (Baltimore), 102(19): e33776. [ DOI:10.1097/MD.0000000000033776] 26. Ran X, Deng Y, Uppuluri NST, et al. (2023) Hotspots and future trends of phosphorus recycling from livestock manure: A bibliometric review. Sci Total Environ, 892: 164346. [ DOI:10.1016/j.scitotenv.2023.164346] 27. Huang P, Wen F, Wu Q, et al. (2023) Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis. Clin Exp Med, 23(7): 3981-3994. [ DOI:10.1007/s10238-023-01110-4] 28. Chen Y, Chen Y, Tan S, et al. (2023) Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022. Hum Vaccin Immunother, 19(1): 2186684. [ DOI:10.1080/21645515.2023.2186684] 29. Fan L, Li B, Li Z, et al. (2021) identification of autophagy related circrna-mirna-mrna-subtypes network with radiotherapy responses and tumor immune microenvironment in non-small cell lung cancer. Front Genet, 12: 730003. [ DOI:10.3389/fgene.2021.730003] 30. Saw SPL, Ong BH, Chua KLM, et al. (2021) Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol, 22(11): e501-e516. [ DOI:10.1016/S1470-2045(21)00383-1] 31. Felip E, Altorki N, Zhou C, et al. (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet, 398(10308): 1344-1357. [ DOI:10.1016/S0140-6736(21)02098-5] 32. Forde PM, Spicer J, Lu S, et al. (2022) neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med, 386(21): 1973-1985. [ DOI:10.1056/NEJMoa2202170] 33. Ettinger DS, Wood DE, Aisner DL, et al. (2023) nccn guidelines® insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw, 21(4): 340-350. [ DOI:10.6004/jnccn.2023.0020] 34. Wakelee H, Liberman M, Kato T, et al. (2023) perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med, 389(6): 491-503. [ DOI:10.1056/NEJMoa2302983] 35. Sorin M, Prosty C, Ghaleb L, et al. (2024) neoadjuvant chemoimmunotherapy for nsclc: a systematic review and meta-analysis. JAMA Oncol, 10(5): 621-633. [ DOI:10.1001/jamaoncol.2024.0057] 36. Sepesi B, Zhou N, William WN, Jr, et al. (2022) Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg, 164(5): 1327-1337. [ DOI:10.1016/j.jtcvs.2022.01.019] 37. Cascone T, William WN, Jr, Weissferdt A, et al. (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med, 27(3): 504-514. [ DOI:10.1038/s41591-020-01224-2] 38. Shu CA, Gainor JF, Awad MM, et al. (2020) Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 21(6): 786-795. [ DOI:10.1016/S1470-2045(20)30140-6] 39. Xu Z, Zou Z, Hao X, et al. (2023) Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. Cancer Innov, 2(1): 65-78. [ DOI:10.1002/cai2.49] 40. Chen Y, Chen S, Li Y, et al. (2024) Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors. International Journal of Radiation Research, 22(2): 449-455. [ DOI:10.61186/ijrr.22.2.455]
Send email to the article author
|
